Morgan Stanley Nanobiotix S.A. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Nanobiotix S.A. stock. As of the latest transaction made, Morgan Stanley holds 2 shares of NBTX stock, worth $10. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 302
99.34%
Holding current value
$10
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding NBTX
# of Institutions
13Shares Held
9.31MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$29.5 Million7.7% of portfolio
-
Baillie Gifford & CO2.87MShares$15 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$2.91 Million0.08% of portfolio
-
Black Rock Inc. New York, NY253KShares$1.33 Million0.0% of portfolio
-
Ubs Group Ag3.1KShares$16,2440.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $183M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...